Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Clinical Translation of SC-DARIC33: A Pharmacologically Controlled CD33-Targeted Anti-AML CAR T Cell Product Regulated By Low Nanomolar Concentrations of Rapamycin

Jacob S. Appelbaum, April Price, Joy Zhang, Kaori Oda, Sumati Sundaram, Paula Lewis, Sanela Bilic, Giacomo Tampella, Dong Xia, Anne-Rachel Krostag, Pauline So, Unja Martin, Wai-Hang Leung, Alexander Astrakhan, Mark Pogson, Jordan Jarjour, Josh Gustafson, Michael CV Jensen

Blood (2021) 138 (Supplement 1): 905.

https://doi.org/10.1182/blood-2021-154461

Published: 2021

Journal Articles

A Phase 1 Study of CFT7455, a Novel Degrader of IKZF1/3, in Multiple Myeloma and Non-Hodgkin Lymphoma

Jesus Berdeja, Sikander Ailawadhi, Steven M. Horwitz, Jeffrey V. Matous, Neha Mehta-Shah, Thomas Martin, Eli Muchtar, Paul G. Richardson, Shambavi Richard, Manisha Bhutani, Andrew J. Yee, Michael R. Palmer, Cathleen Gorman, Oliver Schoenborn-Kellenberger, Sanela Bilic, Adam Crystal, Michelle Mahler, Sagar Lonial

Blood (2021) 138 (Supplement 1): 1675.

https://doi.org/10.1182/blood-2021-153575

Published: 2021

Journal Articles

Early Evidence of Anabolic Bone Activity of BHQ880, a Fully Human Anti-DKK1 Neutralizing Antibody: Results of a Phase 2 Study in Previously Untreated Patients with Smoldering Multiple Myeloma At Risk for Progression

Nikhil C. Munshi, MD, Rafat Abonour, MD, Joseph T. Beck, MD, William Bensinger, MD, Thierry Facon, MD, Keith Stockerl-Goldstein, MD, Rachid Baz, MD, David S Siegel, MD, PhD., Kai Neben, MD, Sagar Lonial, MD, Attaya Suvannasankha, MD, Sanela Bilic, PharmD, Sandra Chica, Subhendu Mukhopadhyay, Randi Isaacs, Sundar Jagannath, MD

Blood (2012) 120 (21): 331.

https://doi.org/10.1182/blood.V120.21.331.331

Published: 2012

Journal Articles

A Phase I/II Study of BHQ880, a Novel Osteoblat Activating, Anti-DKK1 Human Monoclonal Antibody, in Relapsed and Refractory Multiple Myeloma (MM) Patients Treated with Zoledronic Acid (Zol) and Anti-Myeloma Therapy (MM Tx).

Swaminathan Padmanabhan, MD, MBBS, Joseph Thaddeus Beck, MD, Kevin R. Kelly, MD, Nikhil C. Munshi, MD, Andy Dzik-Jurasz, Esha Gangolli, Seth Ettenberg, Kelly Miner, Sanela Bilic, Winston Whyte, Fazal Mehdi, Lu-May Chiang, Patricia Liz Rae, BSc, Andrew Spencer, Jatin Shah, MD, Kenneth C. Anderson, MD, Francis J. Giles, MB, MD, FRCPI, FRCPath, A. Keith Stewart, MBChB

Blood (2009) 114 (22): 750.

https://doi.org/10.1182/blood.V114.22.750.750

Published: 2009

Journal Articles

Pharmacokinetics and Pharmacodynamics from a First-in-Human Phase 1 Dose Escalation Study with Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12), in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia.

John C. Byrd, MD, Ian W. Flinn, MD, Khuda D. Khan, MD, Thomas J. Kipps, MD, Lea Aukerman, PhD, Judith Fox, PhD, Sandhya Girish, PhD, Serge Guzy, PhD, Sanela Bilic, PharmD, Alan Solinger, MD, Sherri Dort, BS, Yongyu Wang, MD, Deborah Hurst, MD, Susan O’Brien, MD

Blood (2006) 108 (11): 2837.

https://doi.org/10.1182/blood.V108.11.2837.2837

Published: 2006

Journal Articles

A Phase 1 Dose Escalation Study of a Fully Human, Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12) in Patients with Relapsed and Refractory Multiple Myeloma.

William Bensinger, MD, Sundar Jagannath, MD, Pamela S. Becker, MD, PhD, Kenneth C. Anderson, MD, Edward A. Stadtmauer, MD, Lea Aukerman, PhD, Judith Fox, PhD, Sandhya Girish, PhD, Sanela Bilic, PharmD, Serge Guzy, PhD, Alan Solinger, MD, Sherri Dort, BS, Yongyu Wang, MD, Deborah Hurst, MD

Blood (2006) 108 (11): 3575.

https://doi.org/10.1182/blood.V108.11.3575.3575

Published: 2006

Journal Articles

The Effects of Zoledronic Acid Dose and Infusion Rate on Pharmacokinetics (PK), Pharmacodynamics (PD), and Renal Function in Patients with Multiple Myeloma.

James R. Berenson, Pierre Major, Regina A. Swift, Robert Vescio, Christina Rivera, Sanela Bilic, Sonia Gauron, Jannick Denouel, Horst Schran

Blood (2005) 106 (11): 5192.

https://doi.org/10.1182/blood.V106.11.5192.5192

Published: 2005

Journal Articles

The Effect of Increasing Zoledronic Acid Dose and Infusion Rate on Pharmacokinetics, Pharmacodynamics, and Renal Function in Patients with Multiple Myeloma.

James Berenson, Pierre Major, Christina Ravera, Sanela Bilic, Horst Schran

Blood (2004) 104 (11): 4939.

https://doi.org/10.1182/blood.V104.11.4939.4939

Published: 2004

NARROW

Clinical Translation of SC-DARIC33: A Pharmacologically Controlled CD33-Targeted Anti-AML CAR T Cell Product Regulated By Low Nanomolar Concentrations of Rapamycin

A Phase 1 Study of CFT7455, a Novel Degrader of IKZF1/3, in Multiple Myeloma and Non-Hodgkin Lymphoma

Early Evidence of Anabolic Bone Activity of BHQ880, a Fully Human Anti-DKK1 Neutralizing Antibody: Results of a Phase 2 Study in Previously Untreated Patients with Smoldering Multiple Myeloma At Risk for Progression

A Phase I/II Study of BHQ880, a Novel Osteoblat Activating, Anti-DKK1 Human Monoclonal Antibody, in Relapsed and Refractory Multiple Myeloma (MM) Patients Treated with Zoledronic Acid (Zol) and Anti-Myeloma Therapy (MM Tx).

Pharmacokinetics and Pharmacodynamics from a First-in-Human Phase 1 Dose Escalation Study with Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12), in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia.

A Phase 1 Dose Escalation Study of a Fully Human, Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12) in Patients with Relapsed and Refractory Multiple Myeloma.

The Effects of Zoledronic Acid Dose and Infusion Rate on Pharmacokinetics (PK), Pharmacodynamics (PD), and Renal Function in Patients with Multiple Myeloma.

The Effect of Increasing Zoledronic Acid Dose and Infusion Rate on Pharmacokinetics, Pharmacodynamics, and Renal Function in Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only